Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

709 results about "Targeting ligands" patented technology

Targeting ligands for disease-targeted imaging agents and methods of use therefor

In accordance with at least one aspect of this disclosure, there is provided an imaging agent, a including dye compound conjugated to an antigen specific targeting vector which can be particularly advantageous because their behavior in vivo can contribute to superior optical imaging properties, for example, by significantly increasing the target-to-background ratio of imaged tissues, leading to higher resolution imaging, and ultimately providing for better recognition of malignant tissue for resection and margin assessment and improved visualization during minimal invasive laparoscopic surgery, for example. A method of imaging tumor cells in a subject, can include, administering an imaging effective amount of an imaging agent according at least one embodiment of the invention; 2-4 hours after administration of the imaging agent, irradiating a region in the subject in which tumor cells are expected to be found with at a wavelength absorbed by the imaging agent; and detecting a signal from the imaging agent, thereby imaging the tumor cells, wherein the target-to-background ratio 2-4 hours after administration is from about 2.75 to about 15.
Owner:CURADEL SURGICAL INNOVATIONS INC

Disease-targeted imaging agents

The invention is based, at least in part, on the discovery that replacement of a key bond in the near-infrared fluorophore with a carbon-carbon bond conjugation to a targeting ligand results in vastly increased stability as compared to NIR fluorophores without such a bond, while preserving ligand and zwitterionic properties. In at least one aspect, the invention provides an imaging agent dye comprising a charge-balanced imaging agent conjugated to a targeting vector, wherein the targeting vector is a PSMA binding vector, such as dPSMA-617 or KUE, a FAP binding vector, a bombesin receptor binding vector, or a somatostatin receptor binding vector, and the charge-balanced imaging agent is ZW-800-1, ZW-830-1, or ZW-700-1-Forte.
Owner:CURADEL SURGICAL INNOVATIONS INC

Compound as well as preparation method and application thereof

The invention relates to the field of nucleic acid medicines, and particularly discloses a compound as shown in a formula (I) as well as a preparation method and application thereof. The targeting ligand and the RNAi medicine prepared from the compound provided by the invention can highly and effectively target parenchymal hepatic cells, can effectively inhibit the expression of target genes in the parenchymal hepatic cells, can be used for treating and / or preventing hepatogenic diseases, and have the advantages of high in-vivo activity, stable and lasting drug effect, excellent safety and low toxicity. # imgabs0 #
Owner:RIGERNA THERAPEUTICS (BEIJING) CO LTD

Engineered bionic exosome with anti-aging effect as well as preparation method and application of engineered bionic exosome

The invention belongs to the technical field of biological medicine, and discloses an engineering bionic exosome with an anti-aging effect and a preparation method and application thereof, and the preparation method comprises the following steps: (S1) preparing a bionic cell membrane modified targeting ligand: adding collagen, mitochondrial targeting polypeptide, a condensing agent and 4-dimethylaminopyridine into an organic solvent, and stirring to obtain the bionic cell membrane modified targeting ligand; activating under a protective atmosphere, and then adding lysine into the system to react, so as to obtain a bionic cell membrane modified targeting ligand; and (S2) embedding the bionic cell membrane modified targeting ligand into the engineered exosome bionic membrane, and entrapping an active substance to form the engineered bionic exosome. The exosome provided by the invention has better skin permeability, mitochondrial targeting effect and cell endocytosis effect, has better protection effect on mitochondria, and can realize efficient delivery of active substances.
Owner:GUANGZHOU ZHONGZHUANG BEAUTY COSMETICS CO LTD +1

Bionic exosome for anti-inflammatory and repair as well as preparation method and application of bionic exosome

The invention relates to a bionic exosome for anti-inflammation and repair as well as a preparation method and application thereof, and belongs to the field of cosmetics. The bionic exosome provided by the invention comprises a membrane structure and an internal load phase, the membrane structure comprises a phospholipid bilayer, a stabilizer and a targeting ligand; the internal load phase comprises a solvent and an active component; the phospholipid bilayer is composed of phospholipid compounds; preferably, at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound, and at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound; at least one of cholesterol, phytosphingosine and sodium stearoyl glutamate is preferably adopted as a stabilizer, so that the stabilizer of the obtained bionic exosome is improved, and the bionic exosome has the advantages of high encapsulation efficiency, good encapsulation efficiency stability, simplicity in operation, excellent anti-inflammatory and repairing effects and the like.
Owner:GUANGZHOU FANZHIRONG COSMETICS CO LTD +1

RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.
Owner:ARROWHEAD PHARMACEUTICALS INC

Cerium oxide-based nano material for bone defect repair, preparation method of cerium oxide-based nano material and cerium oxide-based composite bone scaffold

The invention discloses a cerium oxide-based nano material for bone defect repair and a preparation method of the cerium oxide-based nano material. The cerium oxide-based nano material for bone defect repair is prepared by performing surface modification on cerium oxide-based nano enzyme, and the surface modification comprises introducing a targeting ligand and / or carbon quantum dots into the cerium oxide-based nano enzyme. The invention also discloses a cerium oxide-based composite bone scaffold. The cerium oxide-based composite bone scaffold is prepared by compounding the cerium oxide-based nano-enzyme and / or the cerium oxide-based nano-material and the bone tissue engineering material.
Owner:NANKAI UNIV

Selective histone deacylase 8 (HDAC8) degrading agents and methods of use thereof

The present disclosure relates to compounds, compositions and methods for treating diseases or conditions mediated by aberrant histone deacetylase 8 (HDAC8) activity. In some embodiments, the disclosed compounds comprise an HDAC8 targeting ligand TL moiety covalently linked to a degradation determinant moiety that recruits E3 ubiquitin ligase to HDAC8. In some embodiments, the degradation determinant can bind to an E3 ligase, which is a von Hippel-Lindau (VHL) tumor suppressor, and the E3 ligase can bind to an E3 ligase, which is a Von Hippel-Lindau (VHL) tumor suppressor.
Owner:DANA FARBER CANCER INSTITUTE INC

Nanometer delivery device for gastric cancer targeted drug and use method of nanometer delivery device

The invention discloses a nanometer delivery device for a gastric cancer targeted drug and a use method of the nanometer delivery device, and belongs to the technical field of drug targeted delivery. The device comprises a molecular recognition and optimization module which is responsible for accurately recognizing a tumor cell specific molecular marker and providing personalized treatment strategy recommendation; the nano-carrier design module is used for designing multifunctional lipid-polymer hybrid nano-particles and carrying out surface targeting ligand modification; the intelligent drug loading module is used for improving the stability and controllability of drug loading based on a pH / temperature sensitive release mechanism and effectively reducing the toxic influence of non-targeted tissues; the molecular imaging and monitoring module integrates a nanoprobe imaging technology and a quantum dot tracing technology, constructs a treatment-imaging integrated system, realizes real-time dynamic monitoring of a treatment process, and provides instant feedback of a molecular level; and the risk assessment module is used for establishing a safety database and providing dynamic risk assessment of the treatment process through a biological safety assessment system and long-term tracking management.
Owner:SHAANXI CANCER HOSPITAL (SHAANXI INST OF CANCER PREVENTION & TREATMENT) (SHAANXI THIRD PEOPLES HOSPITAL)

Covalent cereblon ligands

This invention provides Degrons and Degraders that covalently bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. In addition, the Degron can be linked to a Targeting Ligand which binds to a Target Protein to provide a Degrader.
Owner:C4 THERAPEUTICS INC

Method and system for re-scoring after docking based on ligand similarity and DTI

The invention relates to the technical field of computer-aided drug design, and particularly discloses a re-scoring method and system after docking based on ligand similarity and DTI, and the method comprises the steps: obtaining a target protein, and retrieving from a database to obtain a template pocket similar to a pocket of the target protein and a corresponding template protein; scoring the target ligand by using the eutectic ligand of the template protein to obtain a similarity score; the target ligand is a potential active ligand of the target protein; carrying out molecular docking on a target protein and a target ligand, obtaining a molecular map through docking conformation, inputting the molecular map into a map attention network, and calculating to obtain a classification result score; and adding the similarity score and the classification result score, and sorting the target ligands from high to low to obtain a re-scoring result. According to the method, the advantages of ligand similarity and drug-target interaction are combined, so that the enrichment capacity and prediction accuracy of docking virtual screening are improved.
Owner:TIANJIN BEIYUN TECH CO LTD

Drug delivery system for treating osteoporosis caused by cell aging as well as preparation method and application of drug delivery system

The invention relates to a drug delivery system for treating osteoporosis caused by cell aging as well as a preparation method and application of the drug delivery system. The drug delivery system comprises a bone targeting ligand modified drug carrier and an anti-bone cell aging drug entrapped in the drug carrier, the bone targeting ligand is selected from any one of alendronate sodium, bisphosphate and analogues thereof, tetracycline, tartrate-resistant acid phosphatase TRAP binding peptide, pregnancy region protein or e-selectin; the anti-osteocyte senescence medicine comprises any one or a combination of at least two of dasatinib, quercetin, metformin, L-ascorbic acid, aspirin or fisetin. According to the prepared drug delivery system, the bioavailability of the drug can be effectively improved, targeted release of the drug in bone tissue is achieved, senescent cell enrichment is reduced, and the bone microenvironment is improved, so that a new strategy is provided for treating osteoporosis caused by cell senescence.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

Targeting system based on biological orthogonal click chemical reaction as well as preparation method and application thereof

The invention discloses a preparation method of a targeting system based on bio-orthogonal chemistry, the targeting system comprises gel GelMA-DBCO modified with a targeting receptor DBCO and nanoparticles NV-N3 modified with a targeting ligand azide group, the preparation method comprises the following steps: respectively dissolving GelMA and DBCO-NHS, mixing, adding triethylamine, and stirring at room temperature for reaction to obtain GelMA-DBCO; the preparation method comprises the following steps: adding GelMA-DBCO into a solution containing a photoinitiator, and carrying out ultraviolet crosslinking to obtain GelMA-DBCO gel; the preparation method comprises the following steps: adding Ac4ManNAz into a culture medium of MSC to obtain mesenchymal stem cells MSC with N3 modified on the surface, digesting and collecting cells, and extruding the MSC by using a liposome extruder to pass through a filter membrane to obtain nano-particles with azido modified on the surface; and purifying by centrifuging, and resuspending to obtain the NV-N3. The invention also provides application of the targeting system in preparation of products for treating spinal cord injury. The targeting system provided by the invention has strong specificity and stability, good biocompatibility and biodegradability, and effectively improves the targeting ability of the nanoparticles in a spinal cord injury area.
Owner:ZHEJIANG UNIV

Polyethylene Glycol Modified Zwitterionic Fluorescent Probe and Application Thereof, and Preparation

The present disclosure is a polyethylene glycol modified zwitterionic fluorescent probe. The core luminescent group of the fluorescent probe of the present disclosure is a heptamethine chain which is connected by a phenoxy bridge and has a rigid ring structure in the center. The two ends of the heptamethine chain are two sulfonic indole groups, and two polyethylene glycol chains are connected with the indole groups. A tumor targeting ligand is connected with a luminescent group through one polyethylene glycol chain and one alkaline amino acid spacer. The probe of the present disclosure can be connected with polypeptides, small molecules and antibodies having a tumor targeting function, thereby achieving near-infrared fluorescence imaging for tumor targeting. The probe of the present disclosure has good druggability, and is extremely suitable for industrial production and clinical promotion.
Owner:BEIJING SONOPHOTONANO MEDICAL TECHNOLOGY CO LTD

Method for identifying targeting ligands based on differential endocytic removal on the vasculature of organs, and ligands identified therewith

The present invention relates to a method for identifying ligands for targeting of a molecule and / or a drug delivery system to specific endothelial cells of at least one desired organ based on selective retention of the peptides on the surface of the desired endothelial cells. Ligands and their use for specific targeting of a molecule or a drug delivery system to a desired organ are also described.
Owner:FUNDACIO INST DE BIOENGINYERIA DE CATALUNYA (IBEC)

Functionalized targeted liposome and application thereof

The invention relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, and the functionalized targeted liposome comprises lipid and a targeted ligand, wherein the targeting ligand can be specifically combined with a TREM2 receptor. According to the lipidosome, the targeting ligand can be specifically combined with the TREM2 receptor, accurate targeting of cells with the surface containing the TREM2 receptor is achieved, it is ensured that the cells directly act on target cells, the accuracy of a delivered substance is further improved, and the lipidosome has the advantages of being targeting, high in stability, small in side effect and high in bioavailability. The functionalized targeted liposome can be applied to the development of drug carriers, pharmaceutical compositions and the like, and has wide application prospects, for example, the liposome is dynamically connected with hydrogel molecules through a borate bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome, and the application prospect is wide. The liposome disclosed by the invention can respond to an inflammatory environment according to pH and ROS changes of a surrounding environment to release the liposome disclosed by the invention, targets cells with TREM2 receptors on the surfaces, namely microglial cells (with the TREM2 receptors on the surfaces) by virtue of the target ligands exposed on the surfaces, regulates the polarization state of the cells, inhibits the polarization of the cells to a pro-inflammatory M1 type and promotes the polarization of the cells to an anti-inflammatory M2 type, so that the anti-inflammatory effect of the liposome is improved. Therefore, the local microenvironment of the spinal cord injury part is improved, and nerve regeneration is promoted.
Owner:BEIJING TSINGHUA CHANGGUNG HOSPITAL

Targeted nanodroplet and microbubble compositions and methods for enrichment, lysis, and extraction of microbial cells

This invention relates to nanodroplet and microbubble particles comprising targeting ligands that bind to a cell of interest. The invention further relates to methods of using the targeted particles for lysis and extraction of cells of interest, such as microbial cells. The invention further relates to methods of using the targeted particles for enrichment of cells of interest, such as microbial cells.
Owner:TRIANGLE BIOTECHNOLOGY INC

Preparation method of deer spleen aminopeptide powder

The invention discloses a preparation method of deer spleen aminopeptide powder in the field of bioactive substance extraction and functional material compositing, and the performance of the deer spleen aminopeptide powder is improved by compositing a multi-stage functional modified material and deer spleen aminopeptide. The preparation method comprises the following steps: cleaning, homogenizing and crushing fresh deer spleen, extracting with a phosphate buffer solution, adjusting the pH value, carrying out enzymolysis, inactivating enzyme, and treating with an ultrafiltration membrane and a nanofiltration membrane in a specific molecular weight range to obtain a concentrated solution; and mixing the concentrated solution with a multi-stage functional modified material under proper conditions, sterilizing, pre-freezing, and freeze-drying to obtain the deer spleen aminopeptide powder. Wherein the modified material is constructed through quaternization modification, nanopore loading, enzyme inhibitor coupling and targeting ligand modification, and has the functions of charge repulsion, steric hindrance, enzyme inhibition and targeting recognition. The deer spleen aminopeptide powder prepared by the invention has high stability and good bioavailability, and is suitable for functional food or health care products.
Owner:CHANGCHUN LUGANG SHENLU BIOTECHNOLOGY CO LTD

Targeted Ligand-Payload Based Drug Delivery for Cell Therapy

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.
Owner:PURDUE RES FOUND

C3-carbon linked glutarimide degronimers for target protein degradation

This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
Owner:C4 THERAPEUTICS INC

Foleon tooth healing targeting nano preparation and preparation process thereof

The invention discloses a frontalon tooth healing targeting nano preparation and a preparation process thereof, belongs to the technical field of nano medicines, and aims to solve the problems that the natural regeneration capacity of teeth is limited and the combination of ethnic drugs and modern biotechnology is caused due to the lack of a targeting inhibition means for USAG-1. Comprising an anti-USAG-1 monoclonal antibody, ethnic drug components and a nano-carrier, the anti-USAG-1 monoclonal antibody is connected to the surface of the nano-carrier through covalent bonds, the ethnic drug components are loaded in the nano-carrier through physical action, and the nano-carrier is a polylactic acid-glycolic acid copolymer or chitosan; the anti-USAG-1 monoclonal antibody is used as a targeting ligand, is high in targeting property, can accurately reach a tooth focus, improves the drug utilization rate, enhances the curative effect, integrates multiple ethnic drug components, exerts a synergistic effect, can increase the contact area between the ethnic drug components and a biological membrane, promotes the absorption and transport of the drug, and improves the bioavailability of the drug. And the medicine can better play a treatment role.
Owner:宝阳

Conjugates for targeting central nervous system

The present invention provides a conjugate comprising: (a) a CNS targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic acid-co-glycolic acid (PLGA), or glucan, and (c) a flavonoid. The present invention also provides a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, optionally (b) an inner shell comprising oligomeric (-)-epigallocatechin gallate (OEGCG), and optionally (c) a CNS disease treatment molecule encapsulated in the inner shell. The invention also provides a method of treating a CNS disease by administering to a subject an effective amount of a nanoparticle composition of the invention. The CNS targeting ligand targets a CNS tissue and delivers an active ingredient to the CNS tissue for treating a CNS pathological condition.
Owner:SUNTEC MEDICAL INC

Composite drug-loaded nano preparation and preparation method thereof

The invention relates to the technical field of biological medicine, in particular to a composite drug-loaded nano preparation and a preparation method thereof. The composite drug-loaded nano-preparation comprises a drug-loaded nano-liposome, and a biological enzyme and a myofibroblast targeting ligand which are loaded on the surface of the drug-loaded nano-liposome, the drug-loaded nano-liposome is a nano-liposome in which an anti-fibrosis drug is encapsulated; the mass ratio of the drug-loaded nano-liposome to the biological enzyme to the myofibroblast targeting ligand is (6-15): (0.5-4): (0-3). According to the invention, a composite drug-loaded nano preparation for pulmonary drug delivery in an aerosol inhalation manner is constructed, and the myofibroblast targeting ligand and the biological enzyme are jointly modified on the surface of the drug-loaded nano liposome; and the composite nano preparation (CLG-CS-FAP-NIN) which has myofibroblast targeting and can degrade excessive collagen in an extracellular matrix is prepared and is used for treating the pulmonary fibrosis.
Owner:HARBIN MEDICAL UNIVERSITY

Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereof

The present disclosure relates to delivery platforms that specifically and efficiently direct multimeric RNAi agent payloads to hepatocytes in a subject, in vivo. The delivery platforms disclosed herein include metabolically stabilized N-Acetylgalactosamine (NAG or GalNAc) targeting ligands conjugated to two or more RNAi agents, to facilitate the delivery of the oligonucleotide-based payloads to cells, including to hepatocytes. Pharmaceutical compositions that include the metabolically stabilized multimeric RNAi agent conjugate delivery platform are also described, as well as methods of use for the treatment of various diseases and disorders where delivery of a therapeutic payload to a hepatocyte is desirable.
Owner:ARROWHEAD PHARMACEUTICALS INC

Chemically stable KETO-amide-based fibroblast activation protein-targeted conjugates, compositions, and methods of use

Keto-amide based FAP-targeted ligands, conjugate comprising same, pharmaceutical compositions comprising same, and methods of use for imaging and treatment.
Owner:PURDUE RES FOUND

Multi-technology combined medication analysis platform for oligonucleotide drugs

The invention discloses a multi-technology combined medication analysis platform of an oligonucleotide drug, which relates to the technical field of drug analysis and is technically characterized by comprising an oligonucleotide drug delivery technology module, a liposome, a polymer nanoparticle or an exosome is selected as a delivery carrier, the surface of the delivery carrier is modified with hydrophilic polyethylene glycol or a targeting ligand, and the oligonucleotide drug delivery technology module is connected with the oligonucleotide drug delivery module. The performance of the material is represented by dynamic light scattering and a transmission electron microscope; the multi-technology platform analysis module integrates RT-qPCR, LC-FL, LC-MS / MS and LC-HRMS technologies, is respectively used for target gene expression quantification, drug distribution tracking, drug principal component quantification and metabolite structure analysis, establishes a cross validation rule, and requires a correlation coefficient R2gt of an LC-MS / MS quantitative result and RT-qPCR expression data; 0.95%, 0.95%; the pharmacokinetic evaluation module constructs a PBPK model to predict human pharmacokinetic parameters, and draws a drug metabolism network diagram in combination with an LC-HRMS metabolite identification result; by integrating various advanced analysis technologies, the problems of low sensitivity, poor specificity and difficult metabolite analysis in the prior art are solved.
Owner:SUZHOU FANGDA NEW DRUG DEV CO LTD

Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders

The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line with the latter aspect, disclosed herein are pharmaceutical compositions and advantageous components thereof that substantially enhance the effective delivery and release of a therapeutic nucleic acid into the right internal compartment of the muscle cell, such as the cytosol and / or the nucleus, in which compartment it can reach and act upon its genetic target. As disclosed herein, this substantially enhanced delivery and release is achieved by a provision of an endosomal-escape-enhancing saponin in the disclosed herein pharmaceutical compositions comprising therapeutic nucleic acids and, optionally, muscle cell-targeting ligands conjugated therewith. As for the first time demonstrated herein, these saponin types not only surprisingly retain their endosomal-escape-enhancing properties in fully differentiated muscle cells but also can in an unconjugated state successfully be delivered thereto together with the therapeutic nucleic acids.
Owner:SAPREME TECH BV

Acoustic-dynamic targeting drug-loaded nanoparticles as well as preparation method and application thereof

The invention provides sonodynamic targeted drug-loaded nanoparticles as well as a preparation method and application thereof, and belongs to the field of targeted drug delivery preparations. The sonodynamic targeting drug-loading nanoparticle provided by the invention comprises a porous carrier, a drug loaded in the porous carrier and a targeting ligand chemically modified on the outer surface of the porous carrier, the porous carrier is a hydrogen bond organic framework; a construction unit of the hydrogen bond organic framework is a metalloporphyrin complex. After the sonodynamic targeting drug-loading nano-particle provided by the invention is injected into a 4T1 tumor-bearing BALB / c mouse body for 6 hours, fluorescence of the sonodynamic targeting drug-loading nano-particle is observed on a tumor, and a signal is continuously enhanced; after 14 days of administration, the tumor growth is obviously inhibited, and good targeting and anti-tumor effects are achieved.
Owner:YANBIAN UNIV

Bicyclic heterocycles and ligands thereof for targeted delivery of therapeutic agents

The present invention provides novel bicyclic heterocycles capable of conjugating to therapeutic agents and targeting ligands thereof for use as medicaments. Methods for their preparation, pharmaceutical compositions comprising the therapeutic compounds, and pharmaceutical uses thereof are disclosed.
Owner:HANSOH BIO LLC +2

Boron atom-labeled compound for targeting fibroblast activating protein as well as preparation method and application of boron atom-labeled compound

The invention relates to the technical field of compound preparation and medicine, in particular to a boron atom-labeled compound for targeting fibroblast activating protein as well as a preparation method and application of the boron atom-labeled compound. The preparation method comprises the following steps: carrying out acid amine condensation on (4-(((2, 5-dioxopyrrolidine-1-yl) oxy) carbonyl) phenyl) boric acid and an FAP targeting ligand to obtain a boron atom-labeled compound targeting the fibroblast activating protein; and the FAP targeting ligand is FAPI-46 or FAP-2286 (Fibroblast Amplified Polymorphism). The compound is easy to prepare, high in purity and good in stability, the content of boron atoms in tumor tissue can be greatly increased, and a treatment basis is provided for boron neutron capture therapy.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV